These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37920833)

  • 1. Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST).
    Strupp M; Churchill GC; Naumann I; Mansmann U; Al Tawil A; Golentsova A; Goldschagg N
    Front Neurol; 2023; 14():1271640. PubMed ID: 37920833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
    Strupp M; Kraus L; Schautzer F; Rujescu D
    J Neurol; 2018 Oct; 265(Suppl 1):80-85. PubMed ID: 29532287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Betahistine Treatment in a Cat Model of Vestibular Pathology: Pharmacokinetic and Pharmacodynamic Approaches.
    Tighilet B; Léonard J; Watabe I; Bernard-Demanze L; Lacour M
    Front Neurol; 2018; 9():431. PubMed ID: 29942281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic pharmacological interventions for Ménière's disease.
    Webster KE; Galbraith K; Harrington-Benton NA; Judd O; Kaski D; Maarsingh OR; MacKeith S; Ray J; Van Vugt VA; Burton MJ
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD015171. PubMed ID: 36827524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose- and application route-dependent effects of betahistine on behavioral recovery and neuroplasticity after acute unilateral labyrinthectomy in rats.
    Antons M; Lindner M; Eilles E; Günther L; Delker A; Branner C; Krämer A; Beck R; Oos R; Wuehr M; Ziegler S; Strupp M; Zwergal A
    Front Neurol; 2023; 14():1175481. PubMed ID: 37538257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Dose Betahistine in Combination With Selegiline Increases Cochlear Blood Flow in Guinea Pigs.
    Kloos B; Bertlich M; Spiegel JL; Freytag S; Lauer SK; Canis M; Weiss BG; Ihler F
    Ann Otol Rhinol Laryngol; 2023 May; 132(5):519-526. PubMed ID: 35656811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).
    Adrion C; Fischer CS; Wagner J; Gürkov R; Mansmann U; Strupp M;
    BMJ; 2016 Jan; 352():h6816. PubMed ID: 26797774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Betahistine in Ménière's Disease or Syndrome: A Systematic Review.
    Van Esch B; van der Zaag-Loonen H; Bruintjes T; van Benthem PP
    Audiol Neurootol; 2022; 27(1):1-33. PubMed ID: 34233329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease].
    Parfenov VA; Zamergrad MV; Kazei DV; Nauta J
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):42-48. PubMed ID: 33459540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using betahistine in the treatment of patients with Menière's disease: a meta-analysis with the current randomized-controlled evidence.
    Devantier L; Hougaard D; Händel MN; Liviu-Adelin Guldfred F; Schmidt JH; Djurhuus B; Callesen HE
    Acta Otolaryngol; 2020 Oct; 140(10):845-853. PubMed ID: 32580600
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic and surgical therapies for patients with Meniere's disease: A systematic review and network meta-analysis.
    Ahmadzai N; Cheng W; Kilty S; Esmaeilisaraji L; Wolfe D; Bonaparte J; Schramm D; Fitzpatrick E; Lin V; Skidmore B; Hutton B
    PLoS One; 2020; 15(9):e0237523. PubMed ID: 32870918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.
    Nauta JJ
    Eur Arch Otorhinolaryngol; 2014 May; 271(5):887-97. PubMed ID: 23778722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
    Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
    Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial.
    Wu P; Cao W; Hu Y; Li H
    BMJ Open; 2019 Jun; 9(6):e026711. PubMed ID: 31217316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betahistine for Menière's disease or syndrome.
    James AL; Burton MJ
    Cochrane Database Syst Rev; 2001; 2001(1):CD001873. PubMed ID: 11279734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.